ASAryan Salahi‐Niri

Aryan Salahi‐Niri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aryan Salahi‐Niri has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Seyed Amir Ahmad Safavi-Naini

    Affiliations Department of Computer Engineering, Data Science and Machine Learning Lab (DML), Sharif University of Technology, Tehran, Iran, Data-Driven and Digital Health (D3M), The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America

    3 shared publications
  • Behnaz Jahanbin

    Cancer Institute, Pathology Department, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran

    2 shared publications
  • Fatemeh Shojaeian

    Sidney Kimmel Comprehensive Cancer Research Center Johns Hopkins School of Medicine Baltimore Maryland USA

    2 shared publications
  • Paniz Zarand

    Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research, Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Tehran Iran

    2 shared publications
  • Shadi Esmaeili

    Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Abbas Yadegar

    Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication

Latest Publications

  • Open Access

    ZnO Q-Dots Nanoparticles: Intensifying ROS Stress to Improve Anticancer Drug Efficacy

    by Davood Bashash, Aryan Salahi-Niri, Zahra Fakhroueian, Shadi Esmaeili

    Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia that is effectively treated with arsenic trioxide (ATO) in combination with all-trans retinoic acid. However, the toxic effects of ATO necessitate exploring safer therapeutic combinations. Nanotechnology offers potential strategies to enhance drug efficacy and safety. Zinc oxide quantum dots (ZnO Q-dots) exhibit properties such as biocompatibility, selectivity, and the ability to induce reactive oxygen species (ROS), which may potentiate anticancer drug effects. Objectives: This study investigated the combined use of ZnO Q-dots and ATO to improve anticancer outcomes in NB4 APL-derived cells. Methods: NB4 cells were treated with varying concentrations of ZnO Q-dots and ATO, either alone or in combination. Cell viability was assessed using the trypan blue exclusion assay and the MTT assay. Proliferation was evaluated using the BrdU assay, and cell cycle distribution was analyzed by flow cytometry. Apoptosis- and autophagy-related markers were assessed using quantitative real-time PCR (qRT-PCR), and ROS levels were measured using a fluorogenic dye. Results: ZnO Q-dots enhanced the antiproliferative and apoptotic effects of ATO in a dose- and time-dependent manner. Combined treatment reduced metabolic activity to 39.7 ± 2.6%, corresponding to approximately 60.3% inhibition relative to controls. Significant upregulation of apoptotic genes (e.g., p53, Bax) and downregulation of anti-apoptotic genes (e.g., Bcl-2) were observed. ROS production was markedly increased, accompanied by induction of autophagy-related genes (ATG-7, Beclin-1). Conclusions: The combination of ZnO Q-dots and ATO enhances anticancer efficacy in APL-derived NB4 cells, primarily by increasing ROS production, apoptosis, and autophagy. These findings suggest a promising therapeutic strategy with improved efficacy compared with that of single-agent treatments.

  • First Report of National Consensus Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Iran

    by Aryan Salahi‐Niri, Anahita Sadeghi, Marjan Mokhtare, Foroogh Alborzi Avanaki, Mohammad Taher, Afsaneh Mirshahvelayati, Mohammad Reza Zali, Amir Sadeghi, Abbas Yadegar

    Background: Helicobacter pylori infection remains a major public health concern in Iran, where high prevalence, alarming antibiotic resistance, and significant gastric cancer burden necessitate a unified and evidence‐based national strategy. Despite the availability of international guidelines, gaps in clinical practice persist due to local epidemiology, resistance patterns, and diagnostic challenges. This study presents the first national Iranian consensus guideline for the diagnosis and management of H. pylori infection. Methods: A multidisciplinary panel of experts from leading Iranian gastroenterology centers convened between August 2023 and October 2025. Using the GRADE framework, the scientific committee conducted systematic literature reviews and formulated evidence‐based statements across diagnostic, therapeutic, and clinical management domains. Consensus was defined as ≥ 80% agreement. Twelve structured meetings, including a final hybrid national consensus conference, were held to refine recommendations. Results: The guideline delivers 35 evidence‐graded statements addressing indications for testing and treatment, optimal diagnostic modalities, and treatment pathways. Key recommendations include a strong preference for non‐invasive testing in patients under 45 without alarm features, endoscopic evaluation with targeted biopsies in high‐risk groups, and confirmation of eradication using urea breath test (UBT) or monoclonal stool antigen test (SAT) at ≥ 4 weeks post‐treatment. Given Iran's high clarithromycin resistance (> 20%), a course of 10–14 days bismuth quadruple therapy (BQT) is recommended as first‐line treatment, with non‐bismuth concomitant therapy as an alternative. Susceptibility‐guided therapy is encouraged when feasible, particularly after treatment failure. High‐dose proton pump inhibitor (PPI) or potassium competitive acid blocker (P‐CAB)‐based acid suppression is emphasized to enhance eradication efficacy. Special considerations are provided for renal/hepatic impairment and drug interactions. Conclusion: This national guideline provides a standardized, evidence‐based framework for improving H. pylori diagnosis and management. By integrating local antimicrobial resistance patterns and practical clinical considerations, the guideline helps optimize eradication rates, reinforce antibiotic stewardship, and contribute to gastric cancer prevention efforts across Iran.


  • Open Access

    Nanotechnology in Hematology: Enhancing Therapeutic Efficacy With Nanoparticles

    by Nima Torabi Fard, Melika Khademi, Aryan Salahi‐Niri, Shadi Esmaeili

    Background and Aims: Hematological malignancies, such as leukemia, lymphoma, and multiple myeloma, contribute significantly to global cancer diagnoses. Despite progress in conventional therapies, such as chemotherapy and immunotherapy, these treatments face limitations, including nonspecific targeting, side effects, and drug resistance. The aim of this review is to explore the potential of nanotechnology, particularly nanoparticles (NPs), to improve therapeutic outcomes for these cancers by enhancing drug delivery and reducing toxicity. Methods: This review examines recent advancements in NP‐based therapies, focusing on their application in hematological malignancies. We discuss different types of NPs, including liposomes, polymeric, and inorganic NPs, for their potential in targeted drug delivery. The review also evaluates the current state of clinical trials and highlights challenges in the translation of nanomedicines from preclinical research to clinical practice. Results: Nanoparticles, with their unique properties, offer significant advantages in drug delivery systems, such as enhanced stability, extended circulation time, and targeted tumor delivery. Various NP formulations have shown promise in clinical trials, including liposomal formulations like Vyxeos for acute myeloid leukemia and Marqibo for Ph‐negative acute lymphoblastic leukemia. However, challenges in toxicity, regulatory hurdles, and large‐scale production still remain. Conclusion: Nanomedicine holds transformative potential in the treatment of hematological malignancies, offering more effective and specific therapies compared to conventional treatments. Continued research is necessary to overcome the clinical challenges and maximize the benefits of NP‐based therapies for patients with blood cancers.


  • Open Access

    Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review

    by Aryan Salahi‐Niri, Paniz Zarand, Fatemeh Shojaeian, Negar Mansouri, Omid Yazdani, Romina Esbati, Seyed Amir Ahmad Safavi‐Naini, Behnaz Jahanbin

    Background and Aims: Breast cancer is the most common cancer and a leading cause of cancer‐related death among women globally. Determining which patients will benefit from chemotherapy remains challenging. Proliferative markers such as Ki‐67, mini chromosome maintenance (MCM) proteins, and proliferating cell nuclear antigen (PCNA) offer valuable insights into tumor growth and treatment response. This review evaluates their clinical roles, with a focus on chemotherapy implications and emerging digital pathology techniques for marker quantification.Methods: A narrative review was conducted by searching PubMed, Scopus, and Google Scholar for studies related to Ki‐67, MCM, PCNA, breast cancer, and chemotherapy. Studies were thematically categorized into five areas. A bibliometric analysis of publications from 2000 to April 2023 was performed using the Bibliometrix R package and VOSviewer to assess research trends and thematic evolution.Results: Eighty studies were included in the narrative synthesis. Ki‐67 is the most commonly used marker, particularly useful in predicting response to neoadjuvant chemotherapy (NAC). MCM proteins show promise for identifying proliferative potential across tumor grades, while PCNA is associated with aggressive tumor features and poor prognosis. Post‐chemotherapy changes in Ki‐67 levels are linked to survival outcomes. Bibliometric analysis revealed a shift in research focus from basic mechanisms to clinical applications and digital quantification.Conclusion: Proliferative markers play an essential role in breast cancer management. Ki‐67 remains a key predictor of chemotherapy response, while MCM and PCNA offer complementary prognostic insights. Integration of these markers with digital pathology and AI‐driven tools may enhance diagnostic accuracy and personalized treatment strategies. Standardization of assessment methods is crucial for broader clinical application.


  • Open Access

    Potential of Proliferative Markers in Pancreatic Cancer Management: A Systematic Review

    by Aryan Salahi‐Niri, Paniz Zarand, Negar Mansouri, Parvaneh Rastgou, Omid Yazdani, Romina Esbati, Fatemeh Shojaeian, Behnaz Jahanbin, Zhaleh Mohsenifar, Hamid Asadzadeh Aghdaei, et al.

    Background and Aims: Pancreatic cancer is an aggressive malignancy with poor prognosis and limited treatment options. Chemotherapy remains a primary therapeutic approach, but patient responses vary significantly, emphasizing the need for reliable biomarkers. This review explores the potential role of proliferative markers, including Ki‐67, PCNA, Cyclin D1, and PHH3, as predictive and prognostic indicators in pancreatic cancer management, aiming to enhance personalized treatment strategies.Methods: We conducted a narrative review by searching Scopus, PubMed, and Google Scholar for studies focusing on Ki‐67, PCNA, Cyclin D1, and PHH3 in relation to pancreatic cancer and chemotherapy. The literature was reviewed to evaluate the role of these markers in predicting chemotherapy response, tumor progression, and overall patient survival.Results: The review highlights the clinical significance of these markers. Ki‐67 and PCNA are associated with cell proliferation, while Cyclin D1 regulates cell cycle progression and PHH3 is linked to mitotic activity. High expression levels of these markers often correlate with increased tumor aggressiveness and poorer patient outcomes. Moreover, they show promise in predicting chemotherapy response, which can inform tailored therapeutic strategies. However, challenges remain, including standardization of detection methods and determination of optimal cutoff values.Conclusion: Proliferative markers such as Ki‐67, PCNA, Cyclin D1, and PHH3 hold potential as predictive and prognostic tools in pancreatic cancer management. Their integration into clinical practice could improve the accuracy of treatment decisions and enhance patient outcomes. Further research and validation are necessary to overcome existing challenges and optimize their application in personalized oncology.


  • Open Access

    Comparative analysis of COVID-19 pneumonia in pregnant versus matched non-pregnant women: radiologic, laboratory, and clinical perspectives

    by Masoomeh Raoufi, Mahsa Hojabri, Danial Samiei Nasr, Hanieh Najafiarab, Aryan Salahi-Niri, Nastaran Ebrahimi, Shideh Ariana, Hamidreza Khodabandeh, Sara Salarian, Mehdi Azizmohammad Looha, et al.

    This study aimed to assess the severity and outcomes of COVID-19 in pregnant women, focusing on laboratory and radiological discrepancies between pregnant women and matched nonpregnant women. In this retrospective cross-sectional analysis, we matched 107 nonpregnant women with 66 pregnant women in terms of age, comorbidities, and the interval between symptom onset and hospital admission. Demographic, clinical, laboratory, and radiological data were collected, and chest CT scans were evaluated using a severity scale ranging from 0 to 5. Logistic regression and adjusted Cox regression models were used to assess the impact of various factors on pregnancy status and mortality rates. Differences in several laboratory parameters, including the neutrophil-to-lymphocyte ratio, liver aminotransferases, alkaline phosphatase, urea, triglycerides, cholesterol, HbA1c, ferritin, coagulation profiles, and blood gases, were detected. Radiologic exams revealed that nonpregnant women had sharper opacities, whereas pregnant women presented with hazy opacities and signs of crypt-organizing pneumonia. A notable difference was also observed in the pulmonary artery diameter. The mortality rate among pregnant women was 4.62%, which was comparable to the 5.61% reported in nonpregnant patients. Compared with nonpregnant patients, pregnancy did not significantly affect the severity or mortality of COVID-19. Our study revealed discernible differences in specific laboratory and imaging markers between pregnant and nonpregnant COVID-19 patients.